Key facts
- Notable investors include Elysian Capital, QUBIS.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BXTAccelyon
- ·The full record, as it builds
Funding rounds
No funding rounds for BXTAccelyon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BXTAccelyon
Provider of prostate biopsy and brachytherapy products designed for prostate cancer therapy to diagnose and treat prostate cancer. The company offers a product for Local Anaesthetic Transperineal biopsies and also provides minimally invasive prostate cancer therapy, seeds and equipment, and time-critical product prescriptions, enabling the NHS, public and private hospitals and clinics to treat and subsequently cure early-stage prostate cancer effectively.
- Sector
- Healthcare
- HQ
- Burnham, United Kingdom
- Founded
- 2013
- Employees
- 27
- Website
- bxta.com/
- Ownership
- Privately Held (backing)
BXTAccelyon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BXTAccelyon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BXTAccelyon in its N-PORT filings yet. We sweep new filings monthly.